Will Vietnam be transferred to the production technology of XAV-19 polyclonal antibodies to treat COVID-19?
The results of the phase 1 and 2 clinical studies show that the polyclonal XAV-19 antibody ensures safety and has good efficacy in preventing disease progression, neutralizing the virus and reducing inflammation in patients with Covid-19.
.jpg)
The XAV-19 polyclonal antibody ensures safety and is effective in preventing disease progression, neutralizing the virus and reducing inflammation in Covid-19 patients. Illustration
According to information from the Ministry of Health, Deputy Minister Tran Van Thuan has just chaired an online working session with Xenothera Company (France) on cooperation in phase 3 clinical trials and transferring to Vietnam antibody production technology multi-line XAV-19 treatment for COVID-19 researched and developed by the company.
According to the Ministry of Health, XAV-19 infusion suspension is a polyclonal antibody specializing in the treatment of moderate SARS-CoV-2 patients, developed by Xenothera based on its patented antibody production technology, combined with between know-how in the fields of genetics and immunology.
The results of phase 1 and 2 clinical studies show that the drug is safe and effective in preventing disease progression, neutralizing the virus and reducing inflammation in patients. The polyclonal property of XAV-19 has been shown to be effective against the SARS-CoV-2 strains discovered so far.
ctngoc